ChromaDex (CDXC) 10-Q 21 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 28, 2013	Nov. 20, 2013
Document And Entity Information	'	'
Entity Registrant Name	'ChromaDex Corp.	'
Entity Central Index Key	'0001386570	'
Document Type	'10-Q	'
Document Period End Date	28-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-28	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	104,849,075
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 28, 2013	Dec. 29, 2012
Current Assets	'	'
Cash	$1,087,424	$520,000
Trade receivables, less allowance for doubtful accounts and returns September 28, 2013 $10,000; December 29, 2012 $450,000	1,025,619	1,940,539
Inventories	2,217,698	5,205,304
Prepaid expenses and other assets	346,962	261,297
Total current assets	4,677,703	7,927,140
Leasehold Improvements and Equipment, net	969,755	936,426
Other Noncurrent Assets	'	'
Deposits	43,343	34,773
Long-term investment in affiliate (Note 4)	1,899,523	'
Intangible assets, net	188,363	136,182
Total other noncurrent assets	2,131,229	170,955
Total assets	7,778,687	9,034,521
Current Liabilities	'	'
Accounts payable	2,347,222	3,428,233
Accrued expenses	933,934	876,158
Current maturities of capital lease obligations	113,846	77,259
Customer deposits and other	659,645	310,267
Deferred rent, current	56,026	71,042
Total current liabilities	4,110,673	4,762,959
Capital lease obligations, less current maturities	208,645	148,374
Deferred rent, less current	190,536	129,859
Stockholders' Equity	'	'
Common stock, $.001 par value; authorized 150,000,000 shares; issued and outstanding September 28, 2013 100,819,664 and December 29, 2012 92,140,062 shares	100,820	92,140
Additional paid-in capital	36,579,826	33,617,801
Accumulated deficit	-33,411,813	-29,716,612
Total stockholders' equity	3,268,833	3,993,329
Total liabilities and stockholders' equity	$7,778,687	$9,034,521

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 28, 2013	Dec. 29, 2012
Statement of Financial Position [Abstract]	'	'
Trade receivables, less allowance for doubtful accounts and returns	$10,000	$450,000
Common Stock, Par Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	150,000,000	150,000,000
Common Stock, Shares, Issued	100,819,664	92,140,062
Common Stock, Shares, Outstanding	100,819,664	92,140,062

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Income Statement [Abstract]	'	'	'	'
Sales	$2,718,207	$3,632,244	$7,759,668	$8,087,860
Cost of sales	1,968,020	2,377,991	5,375,903	6,673,127
Gross profit	750,187	1,254,253	2,383,765	1,414,733
Operating expenses:	'	'	'	'
Sales and marketing	505,068	802,171	1,866,051	4,529,251
General and administrative	1,453,611	1,983,720	4,155,792	6,829,359
Loss from investment in affiliate (Note 4)	33,281	'	33,281	'
Operating expenses	1,991,960	2,785,891	6,055,124	11,358,610
Operating loss	-1,241,773	-1,531,638	-3,671,359	-9,943,877
Nonoperating income (expense):	'	'	'	'
Interest income	179	469	679	2,725
Interest expense	-8,669	-6,865	-24,521	-22,692
Nonoperating income (expenses)	-8,490	-6,396	-23,842	-19,967
Net loss	($1,250,263)	($1,538,034)	($3,695,201)	($9,963,844)
Basic and Diluted net loss per common share	($0.01)	($0.02)	($0.04)	($0.11)
Basic and Diluted weighted average common shares outstanding	101,309,939	92,364,418	98,590,008	89,477,758

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount, as restated (Note 2) at Dec. 29, 2012	$92,140	$33,617,801	($29,716,612)	$3,993,329
Beginning Balance, Shares at Dec. 29, 2012	92,140,062	'	'	'
Exercise of stock options, Amount	14	6,755	'	6,769
Exercise of stock options, Shares	13,538	'	'	'
Exercise of warrants, Amount	3,414	713,585	'	716,999
Exercise of warrants,Shares	3,414,283	'	'	'
Share-based compensation, Amount	440	548,212	'	548,652
Share-based compensation, Shares	440,000	'	'	'
Net loss, as restated (Note 2)	'	'	-1,424,072	-1,424,072
Ending Balance, Amount, as restated (Note 2) at Mar. 30, 2013	96,008	34,886,353	-31,140,684	3,841,677
Ending Balance, Shares at Mar. 30, 2013	96,007,883	'	'	'
Exercise of stock options, Amount	250	124,750	'	125,000
Exercise of stock options, Shares	250,000	'	'	'
Exercise of warrants, Amount	4,389	917,360	'	921,749
Exercise of warrants,Shares	4,389,281	'	'	'
Share-based compensation, Amount	160	400,794	'	400,954
Share-based compensation, Shares	160,000	'	'	'
Net loss, as restated (Note 2)	'	'	-1,620,866	-1,020,866
Ending Balance, Amount, as restated (Note 2) at Jun. 29, 2013	100,807	36,329,257	-32,161,550	4,268,514
Ending Balance, Shares at Jun. 29, 2013	100,807,164	'	'	'
Exercise of stock options, Amount	13	6,587	'	6,600
Exercise of stock options, Shares	12,500	'	'	'
Share-based compensation, Amount	'	243,982	'	243,982
Net loss, as restated (Note 2)	'	'	-1,250,263	-1,250,263
Ending Balance, Amount, as restated (Note 2) at Sep. 28, 2013	$100,820	$36,579,826	($33,411,813)	$3,268,833
Ending Balance, Shares at Sep. 28, 2013	100,819,664	'	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 28, 2013	Sep. 29, 2012
Cash Flows From Operating Activities	'	'
Net loss	($3,695,201)	($9,963,844)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation of leasehold improvements and equipment	187,667	247,227
Amortization of intangibles	16,819	11,277
Share-based compensation expense	1,059,653	2,189,917
Loss from disposal of equipment	68,378	1,879
Loss from investment in affiliate (Note 4)	33,281	'
Changes in operating assets and liabilities:	'	'
Trade receivables	931,904	-479,763
Inventories	-479,924	-2,530,839
Prepaid expenses and other assets	-50,991	644,296
Accounts payable	-712,138	588,747
Accrued expenses	72,336	-91,196
Customer deposits and other	349,378	57,311
Deferred rent	45,661	-44,883
Net cash used in operating activities	-2,173,177	-9,369,871
Cash Flows From Investing Activities	'	'
Purchases of leasehold improvements and equipment	-117,523	-13,764
Purchase of intangible assets	-69,000	-52,000
Proceeds from sale of assets	1,000,000	'
Proceeds from investment in affiliate	225,000	'
Net cash provided by (used in) investing activities	1,038,477	-65,764
Cash Flows From Financing Activities	'	'
Proceeds from issuance of common stock, net of issuance costs	'	10,159,838
Proceeds from exercise of stock options	138,369	3,059
Proceeds from exercise of warrants	1,638,748	157,500
Principal payments on capital leases	-74,993	-67,843
Net cash provided by financing activities	1,702,124	10,252,554
Net increase in cash	567,424	816,919
Cash Beginning of Period	520,000	420,152
Cash Ending of Period	1,087,424	1,237,071
Supplemental Disclosures of Cash Flow Information	'	'
Cash payments for interest	24,521	22,692
Supplemental Schedule of Noncash Investing Activity	'	'
Capital lease obligation incurred for the purchase of equipment	171,851	50,786
Supplemental Schedule of Noncash Share-based Compensation	'	'
Stock awards issued for services prior to the period	14,560	'
Changes in stock and warrant awards issued for future services	119,375	'
Supplemental Schedule of Noncash Activities Related to Sale of BlueScience Consumer Product Line	'	'
Assets transferred	3,526,677	'
Liabilities transferred	368,873	'
Carrying value of long-term investment in affiliate, net of $1,000,000 cash proceeds	$2,157,804	'

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Parenthetical) (USD $)	9 Months Ended
	Sep. 28, 2013
Statement of Cash Flows [Abstract]	'
Cash proceeds	$1,000,000

Interim_Financial_Statements

Interim Financial Statements	9 Months Ended
	Sep. 28, 2013
Interim Financial Statements	'
Note 1. Interim Financial Statements	'
	The accompanying financial statements of ChromaDex Corporation (the “Company”) and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. include all adjustments, consisting of normal recurring adjustments and accruals, that, in the opinion of the management of the Company, are necessary for a fair presentation of the Company’s financial position as of September 28, 2013 and results of operations and cash flows for the three and nine months ended September 28, 2013 and September 29, 2012. These unaudited interim financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 29, 2012 appearing in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on March 29, 2013. Operating results for the nine months ended September 28, 2013 are not necessarily indicative of the results to be achieved for the full year ending on December 28, 2013. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
	The balance sheet at December 29, 2012 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.

Restatement_of_Previously_Issu

Restatement of Previously Issued Financial Statements	9 Months Ended
	Sep. 28, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Note 2. Restatement of Previously Issued Financial Statements	'
	On November 18, 2013, during the review of the interim financial statements, the Company determined that the previously issued financial statements for the three month period and the six month period ending March 30, 2013 and June 29, 2013, respectively, contained in the Company’s Quarterly Reports on Form 10-Q (“ Quarterly Reports”) for the period ended March 30, 2013 (as filed with the Securities and Exchange Commission on May 10, 2013) and June 29, 2013 (as filed with the Securities and Exchange Commission on August 13, 2013), respectively, should no longer be relied upon because of certain non-cash errors in the Quarterly Reports and that those financial statements (the “Financial Statements”) would be restated to make the necessary accounting adjustments.
	The financial statements filed for the three month period ended March 30, 2013 and the six month period ended June 29, 2013 contained a misstatement pertaining to the accounting treatment of the sale of the BluScience assets to NeutriSci International, Inc. (“NeutriSci”) (See Note 4). The value of the equity and the senior secured convertible note that the Company received from NeutriSci as part of the purchase price were originally accounted for at their stated values which resulted in the Company recognizing a gain on the sale of the BluScience assets. Due to the inability to make a reliably determinable estimate of the fair value of the NeutriSci equity securities and the ultimate collectability of the note received as consideration, management has determined that the proper accounting for the sale transaction is the cost recovery method. Under the cost recovery method, no gain on the sale will be recognized until the Company’s cost basis in the net assets sold has been recovered. In addition, the Company originally accounted for its investment in NeutriSci under the cost method where it has now be determined that the equity method should have been used. The Company expects all amendments and restatements to the Financial Statements affected to be non-cash in nature.
	The Company has determined that the restatements of its Financial Statements resulted from a material weakness in its internal control over financial reporting, specifically related to its process and procedures related to the accounting for sale of assets in exchange for non-cash consideration. More information regarding the Company’s controls and procedures is set forth in Part I, Item 4 of this Form 10-Q.
	The necessary accounting adjustments have been made to the Company’s financial statements for the nine month period ended September 28, 2013 presented in this Form 10-Q.
	The Company will restate the Financial Statements to correct the errors noted above and file amendments to the previous periods Quarterly Reports with the Securities and Exchange Commission as soon as practicable. The correction of the errors will restate the previously issued Financial Statements as follows:
	Statement of Operations (Unaudited)
	For the Three Month Period Ended March 30, 2013
		Previously Reported			Restatement			As Restated
					Adjustments
	Sales	$	2,334,566		$	-		$	2,334,566
	Gross profit		672,840			-			672,840
	Net income (loss)	$	1,468,525		$	(2,892,597	)	$	(1,424,072	)
	Basic net income (loss) per common share	$	0.02		$	(0.03	)	$	(0.02	)
	Diluted net income (loss) per common share	$	0.01		$	(0.03	)	$	(0.02	)
	Statement of Operations (Unaudited)
	For the Three Month Period Ended June 29, 2013
		Previously Reported			Restatement			As Restated
					Adjustments
	Sales	$	2,706,896		$	-		$	2,706,896
	Gross profit		960,738			-			960,738
	Net loss	$	(989,722	)	$	(31,144	)	$	(1,020,866	)
	Basic and Diluted net loss per common share	$	(0.01	)	$	(0.00	)	$	(0.01	)
	Statement of Operations (Unaudited)
	For the Six Month Period Ended June 29, 2013
		Previously Reported			Restatement			As Restated
					Adjustments
	Sales	$	5,041,462		$	-		$	5,041,462
	Gross profit		1,633,578			-			1,633,578
	Net income (loss)	$	478,803		$	(2,923,741	)	$	(2,444,938	)
	Basic net income (loss) per common share	$	0		$	(0.03	)	$	(0.03	)
	Diluted net income (loss) per common share	$	0		$	(0.03	)	$	(0.03	)
	Balance Sheet (Unaudited)
	30-Mar-13
		Previously Reported			Restatement			As Restated
					Adjustments
	Total assets	$	10,717,431		$	(2,892,597	)	$	7,824,834
	Total liabilities		3,983,157			-			3,983,157
	Total stockholder's equity	$	6,734,274		$	(2,892,597	)	$	3,841,677
	Balance Sheet (Unaudited)
	29-Jun-13
		Previously Reported			Restatement			As Restated
					Adjustments
	Total assets	$	10,945,473		$	(2,923,741	)	$	8,021,732
	Total liabilities		3,753,218			-			3,753,218
	Total stockholder's equity	$	7,192,255		$	(2,923,741	)	$	4,268,514

Nature_of_Business_and_Signifi

Nature of Business and Significant Accounting Policies	9 Months Ended
	Sep. 28, 2013
Nature Of Business And Significant Accounting Policies	'
Note 3. Nature of Business and Significant Accounting Policies [Text Block]	'
	Nature of business:  The Company is a natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its business model that utilizes its wholly owned business units, including ingredient technologies, natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting.  The Company provides science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries at various terms.
	Basis of presentation:  The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company's fiscal year ends on the Saturday closest to December 31, and the Company’s normal fiscal quarters end on the Saturday 13 weeks after the last fiscal year end or fiscal quarter end.  Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Company’s floating year-end date.  The fiscal year 2014 will include 53 weeks instead of the normal 52 weeks.
	Trade accounts receivable:  Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on monthly and quarterly reviews of all outstanding amounts.  Management determines the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts.  The allowances for doubtful accounts for the periods ended September 28, 2013 and December 29, 2012 were $10,000 and $450,000, respectively.  Of the allowance amount of $450,000 for the period ended December 29, 2012, $433,000 represents a hold on the receivables placed by a retailer that carried the BluScience consumer product line.  The hold was placed by the retailer as an offset in the event of future returns of our products and the hold was treated as a reduction of revenue. On March 28, 2013, we sold the BluScience retail consumer line to NeutriSci International Inc. (“NeutriSci”) and the related trade accounts receivable including the allowance have been transferred to NeutriSci. Trade accounts receivable are written off when deemed uncollectible.  Recoveries of trade accounts receivable previously written off are recorded when received.
	Inventories:  Inventories are comprised of raw materials, work-in-process and finished goods.  They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market.  The inventory on the balance sheets is recorded net of valuation allowances of $227,000 and $366,000 for the periods ended September 28, 2013 and December 29, 2012, respectively.  Labor and overhead has been added to inventory that was manufactured or characterized by the Company.  On March 28, 2013, the Company sold the BluScience retail consumer line to NeutriSci and related dietary supplements inventory have been transferred to NeutriSci.  The amounts of major classes of inventory as of September 28, 2013 and December 29, 2012 are as follows:
		28-Sep-13		29-Dec-12
	Natural product fine chemicals	$	1,708,606	$	1,614,755
	Bulk ingredients		736,092		432,230
	Dietary supplements – raw materials		-		401,809
	Dietary supplements – work in process		-		465,253
	Dietary supplements – finished goods		-		2,657,257
			2,444,698		5,571,304
	Less valuation allowance		227,000		366,000
		$	2,217,698	$	5,205,304
	Earnings per share: Potentially dilutive common shares consist of the incremental common shares issuable upon the exercise of common stock options and warrants for all periods.   For the three- and nine-month periods ended September 28, 2013 and September 29, 2012, the basic and diluted shares reported are equal because the common share equivalents are anti-dilutive due to the net loss. Below is a tabulation of the potentially dilutive securities that were “in the money” for the three- and nine-month periods ended September 28, 2013 and September 29, 2012.
		Three Months Ended				Nine Months Ended
		28-Sep-13		29-Sep-12		28-Sep-13		29-Sep-12
	Basic weighted average common shares outstanding		101,309,939		92,364,418		98,590,008		89,477,758
	Warrants and options in the money, net		577,190		5,994,067		312,531		5,908,491
	Weighted average common shares outstanding assuming dilution		101,887,129		98,358,485		98,902,539		95,386,249
	Total warrants and options that were not “in the money” at September 28, 2013 and September 29, 2012 were 10,775,361 and 15,214,767, respectively.
	Long-term investment in affiliate: The Company accounts for its investment in affiliate under the equity method. The Company records equity method adjustments in gains (losses) on equity method investments, net, and may do so with up to a three-month lag, pending on the timely availability of financial information of the investee. Equity method adjustments include: our proportionate share of investee income or loss, gains or losses resulting from investee capital transactions, and other adjustments required by the equity method. The long-term investment in affiliate is subject to a periodic impairment review and is considered to be impaired when a decline in carrying value is judged to be other-than-temporary. Evidence of a loss in value might include (i) absence of an ability recover the carrying amount of the investment or (ii) inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.

Sale_of_Product_Line_and_Inves

Sale of Product Line and Investment in Affiliate	9 Months Ended
	Sep. 28, 2013
Sale Of Product Line And Investment In Affiliate	'
Note 4. Sale of Product Line and Investment in Affiliate	'
	On March 28, 2013, the Company entered into an asset purchase and sale agreement with NeutriSci and consummated the sale of the BluScience consumer product line to NeutriSci. The Company is using the cost recovery method to account for the sale transaction, is estimated at approximately $3,157,804. The consideration received consists of following: (a) a $250,000 cash payment, which NeutriSci paid as a deposit in February 2013; (b) an additional $250,000 cash payment, which was paid at the closing of the sale; (c) an additional cash payment of $500,000 due no later than 60 days after the closing of the sale, which has been fully paid as of September 28, 2013; (d) a $2,500,000 senior convertible secured note (convertible into 625,000 shares Series I Preferred Stock as described below) payable in quarterly installments of $416,667 beginning August 15, 2013, which a partial payment of $225,000 was received for the first installment as of September 28, 2013 and an amendment to extend the repayment schedule was executed subsequent to September 28, 2013; and (e) 669,708 shares of Series I Preferred Shares that are convertible into 2,678,832 Class “A” common shares of NeutriSci, representing an aggregate of 19% of the NeutriSci shares at a deemed price for each Class A common share of $1.00 per share at March 28, 2013. The transaction documents contain certain equity blockers that preclude the Company’s ownership in NeutriSci in excess of 9.99% and 19% without obtaining a waiver from NeutriSci. The Company will continue to generate revenue through a royalty on 6% of future net sales of BluScience products as well as a supply agreement with NeutriSci for the Company’s patented pTeroPure pterostilbene. As of September 28, 2013, the Company did not have any sales to NeutriSci under this supply agreement for pTeroPure pterostilbene.
	The Company has applied the equity method of accounting for the 669,708 shares of Series I Preferred Shares that are convertible into 2,678,832 Class “A” common shares of NeutriSci and the carrying value, which includes the senior convertible secured note, is reflected as long-term investment in affiliate in the Company’s consolidated balance sheet as of September 28, 2013. The initial carrying value of this investment recognized, as restated, as of March 28, 2013 was $2,157,804, which is the Company’s unrecovered cost or the difference between the net assets transferred to NeutriSci and the initial monetary consideration received. Although, (i) other contemporaneous third party investments in NeutriSci’s Class “A” common shares were $1.00 per share and (ii) the face value of the senior convertible secured note was $2,500,000, management believed that $2,157,804 was the appropriate aggregate carrying value for the investment in affiliate, considering the fact that NeutriSci is a start-up company and has historically recorded significant operating losses. The Company is unable to determine NeutriSci’s likelihood of repaying the note, and because of this significant uncertainty, the amount of collectability of the senior convertible secured note is not ascertainable. There is a significant uncertainty in the realization of value of the Series I Preferred Shares as well. Consequently, management deemed it appropriate to consider that both the 669,708 shares of Series I Preferred Shares and the senior convertible secured note as one long term investment in affiliate. Under the cost recovery method, no gain on the sale will be recognized until the Company’s cost basis in the net assets transferred has been recovered. The fair value of the senior secured convertible note was not reliably determinable as the prospective collection of payments was significantly uncertain. The below table illustrates how the carrying value was determined. Prospective collection of payments under the note will be charged against the carrying value of the long-term investment in affiliate.
		At March 28, 2013
	Assets transferred
	Trade receivables, less allowance for returns	$	(16,984	)
	Inventories		3,467,530
	Prepaid expenses and other assets		76,131
	Total assets transferred		3,526,677
	Liabilities transferred
	Accounts payable		368,873
	Total liabilities transferred		368,873
	Total net assets transferred	$	3,157,804
	Initial monetary consideration received
	Cash	$	500,000
	Non-trade receivable		500,000
	Total initial monetary consideration received	$	1,000,000
	Carrying Value of Long Term Investment in Affiliate	$	2,157,804
	The Company has elected to record equity method adjustments in gains (losses) on the investment in NeutriSci, with a three-month lag, as the financial information of NeutriSci was not available in a timely manner. At such, for the Company’s three- and nine-month periods ended September 28, 2013, the Company is using NeutriSci’s financial statements for the three-month period from April 1, 2013 through June 30, 2013 to record equity method adjustments for the Company’s ownership since March 28, 2013 as these were the most recent available financial information. As a result, the Company did not record equity method adjustments for the three months ended June 29, 2013. For the nine months ended September 28, 2013, the Company included only the three months of operating results ending in June 30, 2013 of NeutriSci, corresponding to the three-month lag after closing the investment on March 28, 2013. NeutriSci’s financial statements for the period from April 1, 2013 through June 30, 2013 do not cover the three-day period from March 28, 2013 to March 30, 2013, which is also a portion of the Company’s investment period since the Company’s investment started from March 28, 2013. However, the Company has determined that the amount of any impact to the Company for the three day period not covered was immaterial as NeutriSci did not have any significant transactions.
	Unaudited sales, gross profit, net loss of NeutriSci for the three months ended June 30, 2013 and the changes in carrying value and the Company’s ownership percentage through September 28, 2013 are summarized as follows:
		30-Jun-13
	Sales	$	31,669
	Gross profit		12,895
	Net loss	$	(165,579	)
	Changes in Carrying Value and Ownership Percentage for ChromaDex Corporation
		Carrying Value			Ownership
					Percentage
	At March 28, 2013	$	2,157,804			20.1	%
	Company’s share of NeutriSci's loss through June 30, 2013		(33,281	)		-
	Proceeds from investment in affiliates		(225,000	)		-
	At September 28, 2013	$	1,889,523			20.1	%
	The Company’s September 28, 2013 ownership percentage presented in the above table is derived using NeutriSci’s financial information through June 30, 2013.
	As of September 28, 2013, the Company fully received the $500,000 cash payment that was reflected as non-trade receivable as of March 28, 2013.  During the three months ended September 28, 2013, the Company received a partial payment of $225,000 for the first installment of $416,667 that was due on August 15, 2013 under the senior secured convertible note.
	Subsequent to the nine-month period ended September 28, 2013, an amendment to this note was executed in light of NeutriSci’s expected cash flow in the year 2014 and 2015.  The amendment extends the repayment schedule of the outstanding balance with a 6% per annum interest.  The amended repayment schedule is as follows:
	Payable on	Amount
	31-Dec-13	$	34,125
	31-Jan-14		201,375
	31-Mar-14		281,275
	30-Jun-14		270,850
	30-Sep-14		273,775
	31-Dec-14		275,025
	31-Mar-15		286,200
	30-Jun-15		282,150
	30-Sep-15		278,100
	31-Dec-15		274,050
	Total	$	2,456,925
	The senior secured convertible note is secured by the Security Agreement, dated March 28, 2013 entered into between ChromaDex and NeutriSci whereby NeutriSci granted ChromaDex a security interest in substantially all of NeutriSci’s assets, including inventory, to secure its obligations pursuant to the note. In the event of default, the note can also be convertible into Series I Preferred Shares of NeutriSci at the option of ChromaDex. Each Series I Preferred Share can be convertible into 4 Class A common shares of NeutriSci. The conversion price will be (a) $4.00 per Series I Preferred Share prior to a Public Offering (as defined in the note); or (b) the closing price of Series I Preferred Share or four times the closing price of Class A common share on a stock exchange immediately prior to the conversion date.
	Under the asset purchase and sale agreement entered into as of March 28, 2013 with the Company, NeutriSci is obligated to file an initial public offering prospectus with a securities commission in Canada no later than January 31, 2014 and to concurrently seek approval of the listing of its common shares on the TSX Venture Exchange or similar stock exchange in Canada.
	As of September 28, 2013, the Company has determined that there is no other-than-temporary impairment, as the Company is not aware of any other-than-temporary impairment triggering events or indicators.  The Company will continue to monitor NeutriSci’s performance and evaluate if there are any such events or indicators to consider.

Leasehold_Improvements_and_Equ

Leasehold Improvements and Equipment	9 Months Ended
	Sep. 28, 2013
Leasehold Improvements And Equipment	'
Note 5. Leasehold Improvements and Equipment	'
	Leasehold improvements and equipment consisted of the following:
		28-Sep-13		29-Dec-12
	Laboratory equipment	$	2,570,567	$	2,439,688
	Leasehold improvements		491,125		403,971
	Computer equipment		372,851		363,739
	Furniture and fixtures		18,313		18,313
	Office equipment		7,877		7,877
	Construction in progress		99,931		106,080
			3,560,664		3,339,668
	Less accumulated depreciation		2,590,909		2,403,242
		$	969,755	$	936,426
	In September 2013, the Company decided to abandon the development of certain modules of the Laboratory Information Management System (or “LIMS”).  In an effort to automate and better track its laboratory services operations, the Company has been trying to implement LIMS since 2008.  From June 2008 through June 2012, the Company has incurred a total cost of $106,080 for the development and implementation of LIMS and this cost has been capitalized as a long term asset in the books, categorized as “Construction in progress.”  The Company did not incur additional costs since June 2012.  The Company decided to abandon certain modules of LIMS as the additional costs expected to complete the development was greater than the anticipated future benefits from the operation efficiency.  The carrying value of these abandoned modules was $68,378 and was recognized as loss from disposal of equipment in general and administrative expenses in the statement of operations for the three and nine months ended September 28, 2013.

Employee_ShareBased_Compensati

Employee Share-Based Compensation	9 Months Ended
	Sep. 28, 2013
Employee Share-Based Compensation	'
Note 6. Employee Share-Based Compensation [Text Block]	'
	Stock Option Plans
	At the discretion of the Company’s compensation committee (the “Compensation Committee”), and with the approval of the Company’s board of directors (the “Board of Directors”), the Company may grant options to purchase the Company’s common stock to certain individuals from time to time. Management and the Compensation Committee determine the terms of awards which include the exercise price, vesting conditions and expiration dates at the time of grant. Expiration dates for stock options are not to exceed 10 years from their date of issuance. The Company, under its Second Amended and Restated 2007 Equity Incentive Plan, is authorized to issue stock options that total no more than 20% of the shares of common stock issued and outstanding, as determined on a fully diluted basis.  Beginning in 2007, stock options were no longer issuable under the Company’s 2000 Non-Qualified Incentive Stock Plan.  The remaining amount available for issuance under the Second Amended and Restated 2007 Equity Incentive Plan totaled 5,876,180 at September 28, 2013. The stock option awards generally vest ratably over a four-year period following grant date after a passage of time.  However, some stock option awards are performance based and vest based on the achievement of certain criteria established by the Compensation Committee, subject to approval by the Board of Directors.
	The fair value of the Company’s stock options was estimated at the date of grant using the Black-Scholes based option valuation model.  The table below outlines the weighted average assumptions for options granted to employees during the nine months ended September 28, 2013.
	Nine Months Ended September 28, 2013
	Volatility		32.78	%
	Expected dividends		0	%
	Expected term	6.0 years
	Risk-free rate		1.48	%
	The Company calculated expected volatility from the volatility of publicly held companies in similar industries, as the historical volatility of the Company’s common stock does not cover the period equal to the expected life of the options.  The dividend yield assumption is based on the Company’s history and expectation of future dividend payouts on the common stock.  The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining term.  The expected term of the options represents the estimated period of time until exercise and is based on historical experience of awards, giving consideration to the contractual terms, vesting schedules and expectations of future employee behavior.  The estimation process for the fair value of performance based stock options was the same as for service period based options.
	1) Service Period Based Stock Options
	The majority of options granted by the Company are comprised of service based options granted to employees.  These options vest ratably over a defined period following grant date after a passage of a service period.
	The following table summarizes service period based stock options activity at September 28, 2013 and changes during the nine months then ended:
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		12,202,558		$	1.08
	Options Granted		715,000			0.75
	Options Exercised		(26,038	)		0.51
	Options Expired		(75,000	)		0.5
	Options Forfeited		(354,120	)		1.21
	Outstanding at September 28, 2013		12,462,400		$	1.07		7.68	$	431,257
	Exercisable at September 28, 2013		7,784,724		$	1.16		6.88	$	283,574
	The aggregate intrinsic values in the table above are before income taxes, based on the Company’s closing stock price of $0.81 on the last day of business for the period ended September 28, 2013.  The weighted average fair value of options granted during the three and nine months ended September 28, 2013 was $0.28 and $0.26, respectively.  The weighted average fair value of options granted during the three and nine months ended September 29, 2012 was $0.28 and $0.27, respectively.  The aggregate intrinsic value for options exercised during the three and nine months ended September 28, 2013 was $4,775 and $7,212, respectively.  The aggregate intrinsic value for options exercised during the three and nine months ended September 29, 2012 was $765 for both periods as there were no options exercised during the six months ended June 30, 2012.
	2) Performance Based Stock Options
	The Company also grants stock option awards that are performance based and vest based on the achievement of certain criteria established from time to time by the Compensation Committee.  If these performance criteria are not met, the compensation expenses are not recognized and the expenses that have been recognized will be reversed.
	The following table summarizes performance based stock options activity at September 28, 2013 and changes during the nine months then ended:
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		145,834		$	1.59
	Options Granted		200,000			0.63
	Options Exercised		-			-
	Options Expired		-			-
	Options Forfeited		(45,834	)		1.59
	Outstanding at September 28, 2013		300,000		$	0.95		8.75	$	36,000
	Exercisable at September 28, 2013		58,334		$	1.59		7.6	$	-
	The aggregate intrinsic value in the table above are before income taxes, based on the Company’s closing stock price of $0.81 on the last day of business for the period ended September 28, 2013.  The weighted average fair value of options granted during the nine months ended September 28, 2013 was $0.22.  The Company did not grant any performance based stock options during the three months ended September 28, 2013 and the three and nine months ended September 29, 2012.
	As of September 28, 2013, there was $1,806,718 of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans for employee stock options. That cost is expected to be recognized over a weighted average period of 2.53 years as of September 28, 2013.  The realized tax benefit from stock options for the nine months ended September 28, 2013, and September 29, 2012 was $0, based on the Company’s full valuation allowance against its deferred tax assets.
	Restricted Stock
	Restricted stock awards granted by the Company to employees have vesting conditions that are unique to each award.
	The following table summarizes activity of restricted stock awards granted to employees at September 28, 2013 and changes during the nine months then ended:
					Weighted Average
					Award-Date
		Shares			Fair Value
	Unvested shares at December 29, 2012		500,000		$	0.69
	Granted		-			-
	Vested		-			-
	Forfeited		-			-
	Unvested shares at September 28, 2013		500,000		$	0.69
	Expected to Vest as of September 28, 2013		500,000		$	0.69
	As of September 28, 2013, the Company did not have any unrecognized compensation expense related to restricted stock awards to employees.
	For employee share-based compensation, the Company recognized share-based compensation expense of $243,981 and $816,932 in general and administrative expenses in the statement of operations for the three and nine months ended September 28, 2013, respectively.  The Company recognized $455,403 and $1,099,228 in share-based compensation expense for the three and nine months ended September 29, 2012, respectively.

NonEmployee_ShareBased_Compens

Non-Employee Share-Based Compensation	9 Months Ended
	Sep. 28, 2013
Non-Employee Share-Based Compensation	'
Note 7. Non-Employee Share-Based Compensation [Text Block]	'
	Stock Option Plans
	At the discretion of management, working with the Compensation Committee, and with approval of the Board of Directors, the Company may grant options to purchase the Company’s common stock to certain individuals from time to time who are not employees of the Company.  These options are granted under the Second Amended and Restated 2007 Equity Incentive Plan of the Company and are granted on the same terms as those being issued to employees.  Stock options granted to non-employees are accounted for using the fair value approach.  The fair value of non-employee option grants are estimated using the Black-Scholes option-pricing model and are re-measured over the vesting term until earned.  The estimated fair value is expensed over the applicable service period.
	The following table summarizes activity of stock options granted to non-employees at September 28, 2013 and changes during the nine months then ended:
		Weighted Average
		Number of			Exercise		Remaining Contractual		Aggregate Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		1,097,300		$	1.23
	Options Granted		-			-
	Options Exercised		(250,000	)		0.5
	Options Forfeited		-			-
	Outstanding at September 28, 2013		847,300		$	1.44		5.98	$	13,700
	Exercisable at September 28, 2013		847,300		$	1.44		5.98	$	13,700
	The aggregate intrinsic values in the table above are before income taxes, based on the Company’s closing stock price of $0.81 on the last day of business for the period ended September 28, 2013.  The aggregate intrinsic value for options exercised during the nine months ended September 28, 2013 was $35,000.  There were no options exercised during the three months ended September 28, 2013.  There were no options exercised during the three and nine months ended September 29, 2012.
	As of September 28, 2013, the Company did not have any unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans for non-employee stock options.
	Stock Awards
	From time to time, the Company awards shares of its common stock to non-employees for services provided or to be provided.  If the fair value of services received is more reliably measurable than the fair value of the stock awarded, the fair value of the services received is used to measure the award.  In contrast, if the fair value of the stock issued is more reliably measurable, than the fair value of services received, the award is measured based on the fair value of the stock awarded.  Since these stock awards are fully vested and non-forfeitable, upon issuance the measurement date for the award is usually reached on the date of the award.  The measured fair value of the award is amortized over the period the service is provided.
	During the nine months ended September 28, 2013, the Company awarded an aggregate of 600,000 shares of the Company’s common stock to non-employees.  The Company did not award any shares to non-employees during the three months ended September 28, 2013.  The fair values of the awards were based on the trading price of the Company’s stock on the date of issuance.  The expense the Company recognized for stock awards was $87,322 and $237,571 for the three and nine months ended September 28, 2013, respectively.  As of September 28, 2013, there was $142,953 of total unrecognized compensation expense related to stock awarded to the non-employees.  During the three and nine months ended September 29, 2012, the Company awarded an aggregate of 780,294 and 1,234,851 shares, respectively, and recognized a total expense of $372,721 and $680,897, respectively.
	Warrant Awards
	During the nine months ended September 28, 2013, the Company recognized an expense of $4,094 for the warrants that were previously awarded during the year ended December 29, 2012.  The Company did not recognize any expense during the three months ended September 28, 2013.  The Company did not award any new warrants during the three and nine months ended September 28, 2013.  As of September 28, 2013, the Company did not have any unrecognized compensation expense related to warrants awarded to the non-employee.
	For non-employee share-based compensation, the Company recognized share-based compensation expense of $87,322 and $242,721 in general and administrative expenses in the statement of operations for the three and nine months ended September 28, 2013, respectively. The Company recognized $469,989 and $1,090,689 in share-based compensation expense for the three and nine months ended September 29, 2012, respectively.

Warrants

Warrants	9 Months Ended
	Sep. 28, 2013
Warrants	'
Note 8. Warrants	'
	During the nine months ended September 28, 2013, 7,803,564 warrants with an exercise price of $0.21 per share were exercised and the Company received proceeds of $1,638,748 from exercise of these warrants.  These warrants were issued during the year ended January 1, 2011 pursuant to a subscription agreement entered into by the holders of such warrants and the Company on April 22, 2010. There were no warrants exercised during the three months ended September 28, 2013.
	In addition, during the three and nine months ended September 28, 2013, 404,047 and 1,718,350 warrants issued during the year 2008 with an exercise price of $3.00 per share expired, respectively.
	At September 28, 2013, the following warrants were outstanding and exercisable:
	Warrants granted	Weighted Average		Number Outstanding		Weighted Average
	in connection with :	Exercise Prices		And Exercisable		Remaining Contractual Life
				At September 28, 2013
	2012 Placement agent commission	$	0.85		285,000	10.2 months
	2012 Non-employee award	$	0.75		250,000	9.9 months
		$	0.8		535,000	10.0 months

Business_Segmentation

Business Segmentation	9 Months Ended
	Sep. 28, 2013
Business Segmentation	'
Note 9. Business Segmentation	'
	Since the year ended December 29, 2012, the Company began segregating its financial results for Spherix Consulting, Inc. (“Spherix”), which the Company acquired on December 3, 2012.  Spherix provides scientific and regulatory consulting.  The Company has following three reportable segments.
	·   Core standards, contract services and ingredients segment includes supply of phytochemical reference standards, which are small quantities of plant-based compounds typically used to research an array of potential attributes, and reference materials, related contract services, and proprietary ingredients.
	·   Scientific and regulatory consulting segment which consist of providing scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.
	·   Retail dietary supplement products segment which consist of the supply of the BluScience line of dietary supplement products containing the Company’s proprietary ingredients to various retail distribution channels.  On March 28, 2013, the Company entered into an asset purchase and sale agreement with NeutriSci and consummated the sale of BluScience consumer product line to NeutriSci.
	The “Other” classification includes corporate items not allocated by the Company to each reportable segment. Further, there are no intersegment sales that require elimination.  The Company evaluates performance and allocates resources based on reviewing gross margin by reportable segment.
	Three months ended
	28-Sep-13
		Core Standards, Contract Services and			Scientific and Regulatory		Retail Dietary Supplement
		Ingredients segment			Consulting segment		Products segment			Other			Total
	Net sales	$	2,355,458		$	362,749	$	—		$	—		$	2,718,207
	Cost of sales		1,794,073			173,947		—			—			1,968,020
	Gross profit		561,385			188,802		—			—			750,187
	Operating expenses:
	Sales and marketing		493,068			12,000		—			—			505,068
	General and administrative		—			—		—			1,453,611			1,453,611
	Loss from equity investment		—			—		—			33,281			33,281
	Operating expenses		493,068			12,000		—			1,486,892			1,991,960
	Operating income (loss)	$	68,317		$	176,802	$	—		$	(1,486,892	)	$	(1,241,773	)
	Three months ended
	29-Sep-12
		Core Standards, Contract Services and Ingredients segment			Scientific and Regulatory Consulting segment		Retail Dietary Supplement Products segment			Other			Total
	Net sales	$	1,989,910		$	-	$	1,642,334		$	-		$	3,632,244
	Cost of sales		1,539,118			-		838,873			-			2,377,991
	Gross profit		450,792			-		803,461			-			1,254,253
	Operating expenses:
	Sales and marketing		514,029			-		288,142			-			802,171
	General and administrative		-			-		-			1,983,720			1,983,720
	Operating expenses		514,029			-		288,142			1,983,720			2,785,891
	Operating income (loss)	$	(63,237	)	$	-	$	515,319		$	(1,983,720	)	$	(1,531,638	)
	Nine months ended
	28-Sep-13
		Core Standards,Contract Services and Ingredients segment			Scientific and Regulatory Consulting segment		Retail Dietary Supplement Products segment			Other			Total
	Net sales	$	7,011,343		$	808,610	$	(60,285	)	$	-		$	7,759,668
	Cost of sales		4,922,469			452,479		955			-			5,375,903
	Gross profit (loss)		2,088,874			356,131		(61,240	)		-			2,383,765
	Operating expenses:
	Sales and marketing		1,720,292			14,600		131,159			-			1,866,051
	General and administrative		-			-		-			4,155,792			4,155,792
	Loss from investment in affiliate		-			-		-			33,281			33,281
	Operating expenses		1,720,292			14,600		131,159			4,189,073			6,055,124
	Operating income (loss)	$	368,582		$	341,531	$	(192,399	)	$	(4,189,073	)	$	(3,671,359	)
	Nine months ended
	29-Sep-12
		Core Standards,
		Contract Services and			Scientific and Regulatory		Retail Dietary Supplement
		Ingredients segment			Consulting segment		Products segment			Other			Total
	Net sales	$	5,995,243		$	—	$	2,092,617		$	—		$	8,087,860
	Cost of sales		4,413,943			—		2,259,184			—			6,673,127
	Gross profit (loss)		1,581,300			—		(166,567	)		—			1,414,733
	Operating expenses:
	Sales and marketing		1,525,545			—		3,003,706			—			4,529,251
	General and administrative		—			—		—			6,829,359			6,829,359
	Operating expenses		1,525,545			—		3,003,706			6,829,359			11,358,610
	Operating income (loss)	$	55,755		$	—	$	(3,170,273	)	$	(6,829,359	)	$	(9,943,877	)
	At September 28, 2013
		Core Standards,			Scientific		Retail
		Contract Services and			and		Dietary Supplement
					Regulatory
		Ingredients segment			Consulting segment		Products segment			Other			Total
	Total assets	$	3,922,531		$	206,032	$	-		$	3,650,124		$	7,778,687
	At December 29, 2012	Contract Services and Ingredients			Regulatory Consulting		Dietary Supplement Products
		segment			segment		segment			Other			Total
	Total assets	$	3,542,355		$	72,573	$	4,331,866		$	1,087,727		$	9,034,521

Managements_Plans_for_Continui

Managements Plans for Continuing Operations	9 Months Ended
	Sep. 28, 2013
Managements Plans For Continuing Operations	'
Note 10. Managements Plans for Continuing Operations	'
	The Company has incurred a net loss of $3,695,201 for the nine-month period ended September 28, 2013 and an operating loss of $3,671,359 for the nine-month period ended September 28, 2013. One of the factors that contributed to this loss is share-based compensation expense. The Company’s share-based compensation expense totaled $1,059,653 for the nine months ended September 28, 2013. In addition to the stock options granted to employees, the Company has awarded shares of its common stock to non-employees as compensation of the services provided. Another factor that contributed to the loss is patent related expense. The Company’s patent related expenses including maintenance expenses totaled $276,362 for the nine months ended September 28, 2013. The maintenance of the Company’s licensed patents portfolio is critical to the Company’s business model and the Company expects to continue to incur such patent related expenses. Another factor that contributed to the loss is the investment in additional personnel and marketing expenses to implement its business plan to expand the line of proprietary ingredients. This has resulted in higher selling and marketing expenses compared to prior years. Management has also implemented additional strategic operational structure changes, which it believes, will allow the Company to achieve profitability with future growth without incurring significant additional overhead costs. Management’s anticipation of future growth is largely related to the demand of the line of proprietary ingredients offered by the Company. The Company also incurred an operating loss of $192,399 from the BluScience operations. Increase in trade accounts receivable allowance for possible future returns was the main reason for the loss from the BluScience operations as the increase in allowance was treated as a reduction of revenue.
	Subsequent to the nine-month period ended September 28, 2013, the Company sold an aggregate of 3,529,411 shares of the Company’s common stock at a price per share of $0.85 to certain strategic accredited investors for gross proceeds of $3,000,000 or $2,980,000 after deducting offering costs. More information regarding this capital raise is set forth in Note 12 Subsequent Events. The Company anticipates the capital raised from these transactions will be sufficient to implement its current business plan through the end of December, 2014. However, if the Company determines that it shall require additional financing to further enable it to achieve its long-term strategic objectives, there can be no assurance that such financing will be available on terms favorable to it or at all. If adequate financing is not available, the Company will further delay, postpone or terminate product and service expansion and curtail certain selling, general and administrative operations. The inability to raise additional financing may have a material adverse effect on the future performance of the Company.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 28, 2013
Income Taxes	'
Note 11. Income Taxes	'
	At September 28, 2013 and December 29, 2012, the Company maintained a full valuation allowance against the entire net deferred income tax balance after considering relevant factors, including recent operating results, the likelihood of the utilization of net operating loss tax carry forwards, and the ability to generate future taxable income.  The Company expects to maintain a full valuation allowance on its entire net deferred tax assets in 2013, resulting in an effective tax rate of zero for the nine months ended September 28, 2013.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 28, 2013
Subsequent Events [Abstract]	'
Note 12. Subsequent Events	'
	On October 17, 2013, the Company sold an aggregate of 2,941,176 shares of the Company’s common stock, with gross proceeds to the Company of $2,500,000 to a certain strategic accredited investor pursuant to a subscription agreement. Each share of common stock was sold for a purchase price of $0.85 per share.
	On October 18, 2013, the Company sold an aggregate of 588,235 shares of the Company’s common stock, with gross proceeds to the Company of $500,000 to a certain strategic accredited investor pursuant to a subscription agreement. Each share of Common Stock was sold for a purchase price of $0.85 per share on the same terms of the investment made by the strategic accredited investor on October 17, 2013. A cash fee in the amount of $20,000 was paid to a placement agent in connection with this $500,000 investment.

Nature_of_Business_and_Signifi1

Nature of Business and Significant Accounting Policies (Policy)	9 Months Ended
	Sep. 28, 2013
Nature Of Business And Significant Accounting Policies Policy	'
Nature of business	'
	Nature of business:  The Company is a natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its business model that utilizes its wholly owned business units, including ingredient technologies, natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting.  The Company provides science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries at various terms.
Basis of presentation	'
	Basis of presentation:  The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company's fiscal year ends on the Saturday closest to December 31, and the Company’s normal fiscal quarters end on the Saturday 13 weeks after the last fiscal year end or fiscal quarter end.  Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Company’s floating year-end date.  The fiscal year 2014 will include 53 weeks instead of the normal 52 weeks.
Trade accounts receivable	'
	Trade accounts receivable:  Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on monthly and quarterly reviews of all outstanding amounts.  Management determines the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts.  The allowances for doubtful accounts for the periods ended September 28, 2013 and December 29, 2012 were $10,000 and $450,000, respectively.  Of the allowance amount of $450,000 for the period ended December 29, 2012, $433,000 represents a hold on the receivables placed by a retailer that carried the BluScience consumer product line.  The hold was placed by the retailer as an offset in the event of future returns of our products and the hold was treated as a reduction of revenue. On March 28, 2013, we sold the BluScience retail consumer line to NeutriSci International Inc. (“NeutriSci”) and the related trade accounts receivable including the allowance have been transferred to NeutriSci. Trade accounts receivable are written off when deemed uncollectible.  Recoveries of trade accounts receivable previously written off are recorded when received.
Inventories	'
	Inventories:  Inventories are comprised of raw materials, work-in-process and finished goods.  They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market.  The inventory on the balance sheets is recorded net of valuation allowances of $227,000 and $366,000 for the periods ended September 28, 2013 and December 29, 2012, respectively.  Labor and overhead has been added to inventory that was manufactured or characterized by the Company.  On March 28, 2013, the Company sold the BluScience retail consumer line to NeutriSci and related dietary supplements inventory have been transferred to NeutriSci.  The amounts of major classes of inventory as of September 28, 2013 and December 29, 2012 are as follows:
		28-Sep-13		29-Dec-12
	Natural product fine chemicals	$	1,708,606	$	1,614,755
	Bulk ingredients		736,092		432,230
	Dietary supplements – raw materials		-		401,809
	Dietary supplements – work in process		-		465,253
	Dietary supplements – finished goods		-		2,657,257
			2,444,698		5,571,304
	Less valuation allowance		227,000		366,000
		$	2,217,698	$	5,205,304
Earnings per share	'
	Earnings per share: Potentially dilutive common shares consist of the incremental common shares issuable upon the exercise of common stock options and warrants for all periods.   For the three- and nine-month periods ended September 28, 2013 and September 29, 2012, the basic and diluted shares reported are equal because the common share equivalents are anti-dilutive due to the net loss. Below is a tabulation of the potentially dilutive securities that were “in the money” for the three- and nine-month periods ended September 28, 2013 and September 29, 2012.
		Three Months Ended				Nine Months Ended
		28-Sep-13		29-Sep-12		28-Sep-13		29-Sep-12
	Basic weighted average common shares outstanding		101,309,939		92,364,418		98,590,008		89,477,758
	Warrants and options in the money, net		577,190		5,994,067		312,531		5,908,491
	Weighted average common shares outstanding assuming dilution		101,887,129		98,358,485		98,902,539		95,386,249
	Total warrants and options that were not “in the money” at September 28, 2013 and September 29, 2012 were 10,775,361 and 15,214,767, respectively.
Long-term investment in affiliate	'
	Long-term investment in affiliate: The Company accounts for its investment in affiliate under the equity method. The Company records equity method adjustments in gains (losses) on equity method investments, net, and may do so with up to a three-month lag, pending on the timely availability of financial information of the investee. Equity method adjustments include: our proportionate share of investee income or loss, gains or losses resulting from investee capital transactions, and other adjustments required by the equity method. The long-term investment in affiliate is subject to a periodic impairment review and is considered to be impaired when a decline in carrying value is judged to be other-than-temporary. Evidence of a loss in value might include (i) absence of an ability recover the carrying amount of the investment or (ii) inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.

Restatement_of_Previously_Issu1

Restatement of Previously Issued Financial Statements (Tables)	9 Months Ended
	Sep. 28, 2013
Restatement Of Previously Issued Financial Statements Tables	'
Restatement	'
	Statement of Operations (Unaudited)
	For the Three Month Period Ended March 30, 2013
		Previously Reported			Restatement			As Restated
					Adjustments
	Sales	$	2,334,566		$	-		$	2,334,566
	Gross profit		672,840			-			672,840
	Net income (loss)	$	1,468,525		$	(2,892,597	)	$	(1,424,072	)
	Basic net income (loss) per common share	$	0.02		$	(0.03	)	$	(0.02	)
	Diluted net income (loss) per common share	$	0.01		$	(0.03	)	$	(0.02	)
	Statement of Operations (Unaudited)
	For the Three Month Period Ended June 29, 2013
		Previously Reported			Restatement			As Restated
					Adjustments
	Sales	$	2,706,896		$	-		$	2,706,896
	Gross profit		960,738			-			960,738
	Net loss	$	(989,722	)	$	(31,144	)	$	(1,020,866	)
	Basic and Diluted net loss per common share	$	(0.01	)	$	(0.00	)	$	(0.01	)
	Statement of Operations (Unaudited)
	For the Six Month Period Ended June 29, 2013
		Previously Reported			Restatement			As Restated
					Adjustments
	Sales	$	5,041,462		$	-		$	5,041,462
	Gross profit		1,633,578			-			1,633,578
	Net income (loss)	$	478,803		$	(2,923,741	)	$	(2,444,938	)
	Basic net income (loss) per common share	$	0		$	(0.03	)	$	(0.03	)
	Diluted net income (loss) per common share	$	0		$	(0.03	)	$	(0.03	)
	Balance Sheet (Unaudited)
	30-Mar-13
		Previously Reported			Restatement			As Restated
					Adjustments
	Total assets	$	10,717,431		$	(2,892,597	)	$	7,824,834
	Total liabilities		3,983,157			-			3,983,157
	Total stockholder's equity	$	6,734,274		$	(2,892,597	)	$	3,841,677
	Balance Sheet (Unaudited)
	29-Jun-13
		Previously Reported			Restatement			As Restated
					Adjustments
	Total assets	$	10,945,473		$	(2,923,741	)	$	8,021,732
	Total liabilities		3,753,218			-			3,753,218
	Total stockholder's equity	$	7,192,255		$	(2,923,741	)	$	4,268,514

Nature_of_Business_and_Signifi2

Nature of Business and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 28, 2013
Nature Of Business And Significant Accounting Policies Tables	'
Inventories	'
		28-Sep-13		29-Dec-12
	Natural product fine chemicals	$	1,708,606	$	1,614,755
	Bulk ingredients		736,092		432,230
	Dietary supplements – raw materials		-		401,809
	Dietary supplements – work in process		-		465,253
	Dietary supplements – finished goods		-		2,657,257
			2,444,698		5,571,304
	Less valuation allowance		227,000		366,000
		$	2,217,698	$	5,205,304
Earnings per share	'
		Three Months Ended				Nine Months Ended
		28-Sep-13		29-Sep-12		28-Sep-13		29-Sep-12
	Basic weighted average common shares outstanding		101,309,939		92,364,418		98,590,008		89,477,758
	Warrants and options in the money, net		577,190		5,994,067		312,531		5,908,491
	Weighted average common shares outstanding assuming dilution		101,887,129		98,358,485		98,902,539		95,386,249

Sale_of_Product_Line_and_Inves1

Sale of Product Line and Investment in Affiliate (Tables)	9 Months Ended
	Sep. 28, 2013
Sale Of Product Line And Investment In Affiliate	'
Carrying value determination	'
		At March 28, 2013
	Assets transferred
	Trade receivables, less allowance for returns	$	(16,984	)
	Inventories		3,467,530
	Prepaid expenses and other assets		76,131
	Total assets transferred		3,526,677
	Liabilities transferred
	Accounts payable		368,873
	Total liabilities transferred		368,873
	Total net assets transferred	$	3,157,804
	Initial monetary consideration received
	Cash	$	500,000
	Non-trade receivable		500,000
	Total initial monetary consideration received	$	1,000,000
	Carrying Value of Long Term Investment in Affiliate	$	2,157,804
NeutriSci Business information	'
		30-Jun-13
	Sales	$	31,669
	Gross profit		12,895
	Net loss	$	(165,579	)
Change in Carrying Value and Ownership	'
	Changes in Carrying Value and Ownership Percentage for ChromaDex Corporation
		Carrying Value			Ownership
					Percentage
	At March 28, 2013	$	2,157,804			20.1	%
	Company’s share of NeutriSci's loss through June 30, 2013		(33,281	)		-
	Proceeds from investment in affiliates		(225,000	)		-
	At September 28, 2013	$	1,889,523			20.1	%
Note repayment schedule	'
	Payable on	Amount
	31-Dec-13	$	34,125
	31-Jan-14		201,375
	31-Mar-14		281,275
	30-Jun-14		270,850
	30-Sep-14		273,775
	31-Dec-14		275,025
	31-Mar-15		286,200
	30-Jun-15		282,150
	30-Sep-15		278,100
	31-Dec-15		274,050
	Total	$	2,456,925

Leasehold_Improvements_and_Equ1

Leasehold Improvements and Equipment (Tables)	9 Months Ended
	Sep. 28, 2013
Leasehold Improvements And Equipment	'
Leasehold Improvements and Equipment	'
		28-Sep-13		29-Dec-12
	Laboratory equipment	$	2,570,567	$	2,439,688
	Leasehold improvements		491,125		403,971
	Computer equipment		372,851		363,739
	Furniture and fixtures		18,313		18,313
	Office equipment		7,877		7,877
	Construction in progress		99,931		106,080
			3,560,664		3,339,668
	Less accumulated depreciation		2,590,909		2,403,242
		$	969,755	$	936,426

Employee_ShareBased_Compensati1

Employee Share-Based Compensation (Tables)	9 Months Ended
	Sep. 28, 2013
Employee Share-Based Compensation Tables	'
Weighted average assumptions of stock options granted	'
	Nine Months Ended September 28, 2013
	Volatility		32.78	%
	Expected dividends		0	%
	Expected term	6.0 years
	Risk-free rate		1.48	%
Service Period Based Stock Options	'
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		12,202,558		$	1.08
	Options Granted		715,000			0.75
	Options Exercised		(26,038	)		0.51
	Options Expired		(75,000	)		0.5
	Options Forfeited		(354,120	)		1.21
	Outstanding at September 28, 2013		12,462,400		$	1.07		7.68	$	431,257
	Exercisable at September 28, 2013		7,784,724		$	1.16		6.88	$	283,574
Performance Based Stock Options	'
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		145,834		$	1.59
	Options Granted		200,000			0.63
	Options Exercised		-			-
	Options Expired		-			-
	Options Forfeited		(45,834	)		1.59
	Outstanding at September 28, 2013		300,000		$	0.95		8.75	$	36,000
	Exercisable at September 28, 2013		58,334		$	1.59		7.6	$	-
Restricted stock awards granted to employees	'
					Weighted Average
					Award-Date
		Shares			Fair Value
	Unvested shares at December 29, 2012		500,000		$	0.69
	Granted		-			-
	Vested		-			-
	Forfeited		-			-
	Unvested shares at September 28, 2013		500,000		$	0.69
	Expected to Vest as of September 28, 2013		500,000		$	0.69

NonEmployee_ShareBased_Compens1

Non-Employee Share-Based Compensation (Tables)	9 Months Ended
	Sep. 28, 2013
Non-Employee Share-Based Compensation Tables	'
Non-Employee stock options	'
		Weighted Average
		Number of			Exercise		Remaining Contractual		Aggregate Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		1,097,300		$	1.23
	Options Granted		-			-
	Options Exercised		(250,000	)		0.5
	Options Forfeited		-			-
	Outstanding at September 28, 2013		847,300		$	1.44		5.98	$	13,700
	Exercisable at September 28, 2013		847,300		$	1.44		5.98	$	13,700

Warrants_Tables

Warrants (Tables)	9 Months Ended
	Sep. 28, 2013
Warrants Tables	'
Warrants	'
	Warrants granted	Weighted Average		Number Outstanding		Weighted Average
	in connection with :	Exercise Prices		And Exercisable		Remaining Contractual Life
				At September 28, 2013
	2012 Placement agent commission	$	0.85		285,000	10.2 months
	2012 Non-employee award	$	0.75		250,000	9.9 months
		$	0.8		535,000	10.0 months

Business_Segmentation_Tables

Business Segmentation (Tables)	9 Months Ended
	Sep. 28, 2013
Business Segmentation Tables	'
Business Segmentation	'
	Three months ended
	28-Sep-13
		Core Standards, Contract Services and			Scientific and Regulatory		Retail Dietary Supplement
		Ingredients segment			Consulting segment		Products segment			Other			Total
	Net sales	$	2,355,458		$	362,749	$	—		$	—		$	2,718,207
	Cost of sales		1,794,073			173,947		—			—			1,968,020
	Gross profit		561,385			188,802		—			—			750,187
	Operating expenses:
	Sales and marketing		493,068			12,000		—			—			505,068
	General and administrative		—			—		—			1,453,611			1,453,611
	Loss from equity investment		—			—		—			33,281			33,281
	Operating expenses		493,068			12,000		—			1,486,892			1,991,960
	Operating income (loss)	$	68,317		$	176,802	$	—		$	(1,486,892	)	$	(1,241,773	)
	Three months ended
	29-Sep-12
		Core Standards, Contract Services and Ingredients segment			Scientific and Regulatory Consulting segment		Retail Dietary Supplement Products segment			Other			Total
	Net sales	$	1,989,910		$	-	$	1,642,334		$	-		$	3,632,244
	Cost of sales		1,539,118			-		838,873			-			2,377,991
	Gross profit		450,792			-		803,461			-			1,254,253
	Operating expenses:
	Sales and marketing		514,029			-		288,142			-			802,171
	General and administrative		-			-		-			1,983,720			1,983,720
	Operating expenses		514,029			-		288,142			1,983,720			2,785,891
	Operating income (loss)	$	(63,237	)	$	-	$	515,319		$	(1,983,720	)	$	(1,531,638	)
	Nine months ended
	28-Sep-13
		Core Standards,Contract Services and Ingredients segment			Scientific and Regulatory Consulting segment		Retail Dietary Supplement Products segment			Other			Total
	Net sales	$	7,011,343		$	808,610	$	(60,285	)	$	-		$	7,759,668
	Cost of sales		4,922,469			452,479		955			-			5,375,903
	Gross profit (loss)		2,088,874			356,131		(61,240	)		-			2,383,765
	Operating expenses:
	Sales and marketing		1,720,292			14,600		131,159			-			1,866,051
	General and administrative		-			-		-			4,155,792			4,155,792
	Loss from investment in affiliate		-			-		-			33,281			33,281
	Operating expenses		1,720,292			14,600		131,159			4,189,073			6,055,124
	Operating income (loss)	$	368,582		$	341,531	$	(192,399	)	$	(4,189,073	)	$	(3,671,359	)
	Nine months ended
	29-Sep-12
		Core Standards,
		Contract Services and			Scientific and Regulatory		Retail Dietary Supplement
		Ingredients segment			Consulting segment		Products segment			Other			Total
	Net sales	$	5,995,243		$	—	$	2,092,617		$	—		$	8,087,860
	Cost of sales		4,413,943			—		2,259,184			—			6,673,127
	Gross profit (loss)		1,581,300			—		(166,567	)		—			1,414,733
	Operating expenses:
	Sales and marketing		1,525,545			—		3,003,706			—			4,529,251
	General and administrative		—			—		—			6,829,359			6,829,359
	Operating expenses		1,525,545			—		3,003,706			6,829,359			11,358,610
	Operating income (loss)	$	55,755		$	—	$	(3,170,273	)	$	(6,829,359	)	$	(9,943,877	)
	At September 28, 2013
		Core Standards,			Scientific		Retail
		Contract Services and			and		Dietary Supplement
					Regulatory
		Ingredients segment			Consulting segment		Products segment			Other			Total
	Total assets	$	3,922,531		$	206,032	$	-		$	3,650,124		$	7,778,687
	At December 29, 2012	Contract Services and Ingredients			Regulatory Consulting		Dietary Supplement Products
		segment			segment		segment			Other			Total
	Total assets	$	3,542,355		$	72,573	$	4,331,866		$	1,087,727		$	9,034,521

Restatement_of_Previously_Issu2

Restatement of Previously Issued Financial Statements (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Sep. 29, 2012

Sep. 28, 2013

Sep. 29, 2012

Dec. 29, 2012

Jun. 29, 2013

Mar. 30, 2013

Jun. 29, 2013

Jun. 29, 2013

Mar. 30, 2013

Jun. 29, 2013

Jun. 29, 2013

Mar. 30, 2013

Jun. 29, 2013

Scenario, Previously Reported [Member]

Scenario, Previously Reported [Member]

Scenario, Previously Reported [Member]

Restatement Adjustment [Member]

Restatement Adjustment [Member]

Restatement Adjustment [Member]

As Restated [Member]

As Restated [Member]

As Restated [Member]

Statement of Operations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sales

$2,718,207

'

'

$3,632,244

$7,759,668

$8,087,860

'

$2,706,896

$2,334,566

$5,041,462

'

'

'

$2,706,896

$2,334,566

$5,041,462

Gross profit

750,187

'

'

1,254,253

2,383,765

1,414,733

'

960,738

672,840

1,633,578

'

'

'

960,738

672,840

1,633,578

Net income (loss)

-1,250,263

-1,020,866

-1,424,072

-1,538,034

-3,695,201

-9,963,844

'

-989,722

1,468,525

478,803

-31,144

-2,892,597

-2,923,741

-1,020,866

-1,424,072

-2,444,938

Basic net income (loss) per common share

'

'

'

'

'

'

'

'

$0.02

'

'

($0.03)

'

'

($0.02)

'

Diluted net income (loss) per common share

'

'

'

'

'

'

'

'

$0.01

'

'

($0.03)

'

'

($0.02)

'

Basic and diluted net income (loss) per common share

($0.01)

'

'

($0.02)

($0.04)

($0.11)

'

($0.01)

'

$0

$0

'

($0.03)

($0.01)

'

($0.03)

Balance Sheets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total assets

7,778,687

'

'

'

7,778,687

'

9,034,521

10,945,473

10,717,431

10,945,473

-2,923,741

-2,892,597

-2,923,741

8,021,732

7,824,834

8,021,732

Total liabilities

'

'

'

'

'

'

'

3,753,218

3,983,157

3,753,218

'

'

'

3,753,218

3,983,157

3,753,218

Total stockholders' equity

$3,268,833

$4,268,514

$3,841,677

'

$3,268,833

'

$3,993,329

$7,192,255

$6,734,274

$7,192,255

($2,923,741)

($2,892,597)

($2,923,741)

$4,268,514

$3,841,677

$4,268,514

Nature_of_Business_and_Signifi3

Nature of Business and Significant Accounting Policies (Details) (USD $)	Sep. 28, 2013	Dec. 29, 2012
Inventories	'	'
Natural product fine chemicals	$1,708,606	$1,614,755
Bulk ingredients	736,092	432,230
Dietary supplements - raw materials	'	401,809
Dietary supplements - work in process	'	465,253
Dietary supplements - finished goods	'	2,657,257
Inventory-gross	2,444,698	5,571,304
Less valuation allowance	227,000	366,000
Inventory-net	$2,217,698	$5,205,304

Nature_of_Business_and_Signifi4

Nature of Business and Significant Accounting Policies (Details 1)	3 Months Ended		9 Months Ended
	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Earnings per share	'	'	'	'
Basic weighted average common shares outstanding	101,309,939	92,364,418	98,590,008	89,477,758
Warrants and options in the money, net	577,190	5,994,067	312,531	5,908,491
Weighted average common shares outstanding assuming dilution	101,887,129	98,358,485	98,902,539	95,386,249

Nature_of_Business_and_Signifi5

Nature of Business and Significant Accounting Policies (Details Narrative) (USD $)	Sep. 28, 2013	Dec. 29, 2012	Sep. 29, 2012
Nature Of Business And Significant Accounting Policies Details Narrative	'	'	'
Inventory valuation allowances	$227,000	$366,000	'
Not in the money warrants and options	10,775,361	'	12,514,767
Hold on receivable amount	'	433,000	'
Allowance for doubtful accounts	$10,000	$450,000	'

Sale_of_Product_Line_and_Inves2

Sale of Product Line and Investment in Affiliate (Details) (USD $)	Mar. 28, 2013
Assets transferred	'
Trade receivables, less allowance for returns	($16,984)
Inventories	3,467,530
Prepaid expenses and other assets	76,131
Total assets transferred	3,526,677
Liabilities transferred	'
Accounts payable	368,873
Total liabilities transferred	368,873
Total net assets transferred	3,157,804
Initial Monetary Consideration received	'
Cash	500,000
Non-trade receivable	500,000
Total initial monetary consideration received	1,000,000
Carrying Value of Long Term Investment in Affiliate	$2,157,804

Sale_of_Product_Line_and_Inves3

Sale of Product Line and Investment in Affiliate (Details 1) (NeutriSci [Member], USD $)	3 Months Ended
	Jun. 29, 2013
NeutriSci [Member]	'
Sales	$31,669
Gross profit	12,895
Net loss	($165,579)

Sale_of_Product_Line_and_Inves4

Sale of Product Line and Investment in Affiliate (Details 2) (NeutriSci [Member], USD $)	3 Months Ended
	Jun. 29, 2013	Sep. 28, 2013	Dec. 29, 2012
NeutriSci [Member]	'	'	'
Carrying value, equity investment, beginning balance	$2,157,804	$1,899,523	$2,157,804
Company's share of NeutriSci's loss through June 30, 2013	-33,281	'	'
Proceeds from investment in affiliate	-225,000	'	'
Carrying value, equity investment, ending balance	'	$1,899,523	$2,157,804
Ownership percentage, beginning of period	20.10%	20.10%	'
Ownership percentage, end of period	'	20.10%	'

Sale_of_Product_Line_and_Inves5

Sale of Product Line and Investment in Affiliate (Details 3) (USD $)	Sep. 28, 2013
Amount due	$2,456,925
Payment 1 [Member]	'
Amount due	34,125
Payable on	'2013-12-31T00:00:00
Payment 2 [Member]	'
Amount due	201,375
Payable on	'2014-01-31T00:00:00
Payment 3 [Member]	'
Amount due	281,275
Payable on	'2014-03-31T00:00:00
Payment 4 [Member]	'
Amount due	270,850
Payable on	'2014-06-30T00:00:00
Payment 5 [Member]	'
Amount due	273,775
Payable on	'2014-09-30T00:00:00
Payment 6 [Member]	'
Amount due	275,025
Payable on	'2014-12-31T00:00:00
Payment 7 [Member]	'
Amount due	286,200
Payable on	'2015-03-31T00:00:00
Payment 8 [Member]	'
Amount due	282,150
Payable on	'2015-06-30T00:00:00
Payment 9 [Member]	'
Amount due	278,100
Payable on	'2015-09-30T00:00:00
Payment 10 [Member]	'
Amount due	$274,050
Payable on	'2015-12-31T00:00:00

Sale_of_Product_Line_and_Inves6

Sale of Product Line and Investment in Affiliate (Details Narrative) (USD $)	9 Months Ended
	Sep. 28, 2013	Sep. 28, 2013	Mar. 30, 2013
Series I Conversion rate per share	$4	$4	'
NeutriSci [Member]	'	'	'
Sale transaction value	$3,157,804	'	'
Deposit	250,000	'	'
Closing payment	250,000	'	'
Additional payment amount	500,000	'	'
Secured note	2,500,000	'	'
Convertible shares	625,000	'	'
Quarterly installment	416,667	'	'
Series I preferres shares issued	669,708	'	'
Series I conversion into Class A Common Shares	2,678,832	'	'
Class A common percent of deemed shares	19.00%	'	'
Class A price per share	$1	'	'
Royalty due to company on future net sales, rate	6.00%	'	'
Carrying value, equity investment, beginning balance	2,157,804	1,899,523	2,157,804
Cash payment received	500,000	'	'
Partial payment received	$225,000	'	'

Leasehold_Improvements_and_Equ2

Leasehold Improvements and Equipment (Details) (USD $)	Sep. 28, 2013	Dec. 29, 2012
Leasehold Improvements And Equipment Details	'	'
Laboratory equipment	$2,570,567	$2,439,688
Leasehold improvements	491,125	403,971
Computer equipment	372,851	363,739
Furniture and fixtures	18,313	18,313
Office equipment	7,877	7,877
Construction in progress	99,931	106,080
Leasehold Improvements and Equipment-gross	3,560,664	3,339,668
Less accumulated depreciation	2,590,909	2,403,242
Leasehold Improvements and Equipment-net	$969,755	$936,426

Leasehold_Improvements_and_Equ3

Leasehold Improvements and Equipment (Details Narrative) (USD $)	3 Months Ended	9 Months Ended	49 Months Ended
	Sep. 28, 2013	Sep. 28, 2013	Jun. 30, 2012
Leasehold Improvements And Equipment Details Narrative	'	'	'
Cost of development and implementation	'	'	$106,080
Carying value of abandoned assets	$68,378	$68,378	'

Employee_ShareBased_Compensati2

Employee Share-Based Compensation (Details) (Options [Member])	9 Months Ended
	Sep. 28, 2013
Options [Member]	'
Volatility	32.78%
Expected dividends	0.00%
Expected term	'6 years
Risk-free rate	1.48%

Employee_ShareBased_Compensati3

Employee Share-Based Compensation (Details 1) (ServicePeriodBasedStockOptions [Member], USD $)	9 Months Ended
	Sep. 28, 2013
ServicePeriodBasedStockOptions [Member]	'
Number of Shares	'
Outstanding at Beginning of Period	12,202,558
Options Granted	715,000
Options Exercised	-26,038
Options Expired	-75,000
Options Forfeited	-354,120
Outstanding at End of Period	12,462,400
Exercisable at End of Period	7,784,724
Weighted Average Exercise Price	'
Outstanding at Beginning of Period	$1.08
Options Granted	$0.75
Options Exercised	$0.51
Options Expired	$0.50
Options Forfeited	$1.21
Outstanding at End of Period	$1.07
Exercisable at End of Period	$1.16
Weighted Average Remaining Contractual Term	'
Outstanding at End of Period	'7 years 8 months 5 days
Exercisable at End of Period	'6 years 10 months 17 days
Aggregate Intrinsic Value	'
Outstanding at End of Period	$431,257
Exercisable at End of Period	$283,574

Employee_ShareBased_Compensati4

Employee Share-Based Compensation (Details 2) (Performance Based Stock Options [Member], USD $)	9 Months Ended
	Sep. 28, 2013
Performance Based Stock Options [Member]	'
Summary of performance based stock option activity- Shares	'
Outstanding at Beginning of Period	145,834
Options Granted	200,000
Options Exercised	'
Options Expired	'
Options Forfeited	-45,834
Outstanding at End of Period	300,000
Exercisable at End of Period	58,334
Weighted Average Exercise Price	'
Outstanding at Beginning of Period	$1.59
Options Granted	$0.63
Options Exercised	'
Options Expired	'
Options Forfeited	$1.59
Outstanding at End of Period	$0.95
Exercisable at End of Period	$1.59
Weighted Average Remaining Contractual Term	'
Outstanding at End of Period	'8 years 9 months 0 days
Exercisable at End of Period	'7 years 7 months 6 days
Aggregate Intrinsic Value	'
Outstanding at End of Period	$36,000
Exercisable at End of Period	'

Employee_ShareBased_Compensati5

Employee Share-Based Compensation (Details 3) (Restricted Stock [Member], USD $)	9 Months Ended
	Sep. 28, 2013
Restricted Stock [Member]	'
Summary of activity of restricted stock awards granted to employees- Shares	'
Unvested shares at Beginning of Period	500,000
Granted	'
Vested	'
Forfeited	'
Unvested shares at End of Period	500,000
Expected to Vest as of End of Period	500,000
Weighted Average Award-Date Fair Value	'
Unvested shares at Beginning of Period	$0.69
Granted	'
Vested	'
Forfeited	'
Unvested shares at End of Period	$0.69
Expected to Vest as of End of Period	$0.69

Employee_Share_Based_Compensat

Employee Share Based Compensation (Details Narrative) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 28, 2013

Sep. 29, 2012

Sep. 28, 2013

Sep. 29, 2012

Sep. 28, 2013

Sep. 29, 2012

Sep. 28, 2013

Sep. 29, 2012

Sep. 28, 2013

Sep. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

Options [Member]

Options [Member]

ServicePeriodBasedStockOptions [Member]

ServicePeriodBasedStockOptions [Member]

ServicePeriodBasedStockOptions [Member]

ServicePeriodBasedStockOptions [Member]

Performance Based Stock Options [Member]

Restricted Stock [Member]

Expiration dates for stock options not exceeds

'

'

'

'

'10 years

'

'

'

'

'

'

'

Authorized stock options

'

'

'

'

20.00%

'

'

'

'

'

'

'

Remaining amount available for issuance

'

'

'

'

5,876,180

'

'

'

'

'

'

'

Closing stock price

'

'

'

'

'

'

$0.81

'

$0.81

'

$0.81

'

Aggregate intrinsic value of options exercised

'

'

'

'

'

'

$4,775

$765

$7,212

$765

'

'

Unrecognized compensation expense

'

'

'

'

1,806,718

'

'

'

'

'

'

0

Cost is expected to be recognized over a weighted average period

'

'

'

'

'P2Y6M10D

'

'

'

'

'

'

'

Weighted average fair value of options granted

'

'

'

'

'

'

$0.28

$0.28

$0.26

$0.27

$0.22

'

Realized tax benefit from stock options

'

'

'

'

0

0

'

'

'

'

'

'

Recognized share based compensation expense (income)

$243,981

$455,403

$816,932

$1,099,228

'

'

'

'

'

'

'

'

NonEmployee_ShareBased_Compens2

Non-Employee Share-Based Compensation (Details) (USD $)	9 Months Ended
	Sep. 28, 2013
Non-Employee Share-Based Compensation- Options	'
Outstanding at Beginning of Period	1,097,300
Options Granted	'
Options Exercised	-250,000
Options Forfeited	'
Outstanding at End of Period	847,300
Exercisable at End of Period	847,300
Weighted Average Exercise Price	'
Outstanding at Beginning of Period	$1.23
Options Granted	'
Options Exercised	$0.50
Options Forfeited	'
Outstanding at End of Period	$1.44
Exercisable at End of Period	$1.44
Weighted Average Remaining Contractual Term	'
Outstanding at June 29, 2013	'5 years 11 months 23 days
Exercisable at June 29, 2013	'5 years 11 months 23 days
Aggregate Intrinsic Value	'
Outstanding at June 29, 2013	$13,700
Exercisable at June 29, 2013	$13,700

NonEmployee_ShareBased_Compens3

Non-Employee Share-Based Compensation (Details Textuals) (USD $)	3 Months Ended		9 Months Ended
	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
NonEmployee Share Based Compensation [Member] | Stock Options [Member]	'	'	'	'
Closing stock price	$0.81	'	$0.81	'
Aggregate intrinsic value nonemployee options exercised	'	'	$35,000	'
NonEmployee Share Based Compensation [Member] | StockAward [Member]	'	'	'	'
Shares awarded during the period	'	780,294	600,000	1,234,851
Share-based compensation expense	87,322	372,721	237,571	680,897
Unrecognized compensation expense	'	'	142,953	'
NonEmployee Shared Based Compensation [Member] | WarrantAward [Member]	'	'	'	'
Share-based compensation expense	'	'	4,094	'
Unrecognized compensation expense	'	'	'	'
NonEmployee Shared Based Compensation [Member] | GeneralAndAdministrativeExpenses [Member]	'	'	'	'
Share-based compensation expense	$87,322	$469,989	$242,721	$1,090,689

Warrants_Details

Warrants (Details) (USD $)	Sep. 28, 2013
PlacementAgentCommission2012Member	'
Warrants outstanding and exercisable	'
Weighted Average Exercise Prices	$0.85
Number Outstanding And Exercisable At June 29, 2013	285,000
Weighted Average Remaining Contractual Life	'10 months 6 days
NonEmployeeAward2010Member	'
Warrants outstanding and exercisable	'
Weighted Average Exercise Prices	$0.75
Number Outstanding And Exercisable At June 29, 2013	250,000
Weighted Average Remaining Contractual Life	'9 months 27 days
TotalMember	'
Warrants outstanding and exercisable	'
Weighted Average Exercise Prices	$0.80
Number Outstanding And Exercisable At June 29, 2013	535,000
Weighted Average Remaining Contractual Life	'10 months

Warrants_Details_Narrative

Warrants (Details Narrative) (USD $)	3 Months Ended	9 Months Ended
	Sep. 28, 2013	Sep. 28, 2013
Warrants Details Narrative	'	'
Proceeds from exercise of warrants	'	$1,638,748
exercise of warrants, shares	'	7,803,564
Exercise price of warrant	'	$0.21
Warrants expired	404,047	1,718,350
Exercise price of warrants expired	$3	$3

Business_Segmentation_Details

Business Segmentation (Details) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended
	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
					CoreStandardsContractServices [Member]	CoreStandardsContractServices [Member]	CoreStandardsContractServices [Member]	CoreStandardsContractServices [Member]	ScientificRegulatory [Member]	ScientificRegulatory [Member]	ScientificRegulatory [Member]	ScientificRegulatory [Member]	RetailDietarySupp [Member]	RetailDietarySupp [Member]	RetailDietarySupp [Member]	RetailDietarySupp [Member]	Other Segment [Member]	Other Segment [Member]	Other Segment [Member]	Other Segment [Member]
Net sales	$2,718,207	$3,632,244	$7,759,668	$8,087,860	$2,355,458	$1,989,910	$7,011,343	$5,995,243	$362,749	'	$808,610	'	'	$1,642,334	($60,285)	$2,092,617	'	'	'	'
Cost of sales	1,968,020	2,377,991	5,375,903	6,673,127	1,794,073	1,539,118	4,922,469	4,413,943	173,947	'	452,479	'	'	838,873	955	2,259,184	'	'	'	'
Gross profit	750,187	1,254,253	2,383,765	1,414,733	561,385	450,792	2,088,874	1,581,300	188,802	'	356,131	'	'	803,461	-61,240	-166,567	'	'	'	'
Sales and marketing	505,068	802,171	1,866,051	4,529,251	493,068	514,029	1,720,292	1,525,545	12,000	'	14,600	'	'	288,142	131,159	3,003,706	'	'	'	'
General and Administrative	1,453,611	1,983,720	4,155,792	6,829,359	'	'	'	'	'	'	'	'	'	'	'	'	1,453,611	1,983,720	4,155,792	6,829,359
Loss from investment in affiliate	33,281	'	33,281	'	'	'	'	'	'	'	'	'	'	'	'	'	33,281	'	33,281	'
Operating expenses	1,991,960	2,785,891	6,055,124	11,358,610	493,068	514,029	1,720,292	1,525,545	12,000	'	14,600	'	'	288,142	-131,159	3,003,706	1,486,892	1,983,720	4,189,073	6,829,359
Operating income (loss)	($1,241,773)	($1,531,638)	($3,671,359)	($9,943,877)	$68,317	($63,237)	$368,582	$55,755	$176,802	'	$341,531	'	'	$515,319	($192,399)	($3,170,273)	($1,486,892)	($1,983,720)	($4,189,073)	($6,829,359)

Business_Segmentation_Details1

Business Segmentation (Details1) (USD $)	Sep. 28, 2013	Dec. 29, 2012
Total assets	$7,778,687	$9,034,521
CoreStandardsContractServices [Member]	'	'
Total assets	3,922,531	3,542,355
ScientificRegulatory [Member]	'	'
Total assets	206,032	72,573
RetailDietarySupp [Member]	'	'
Total assets	'	4,331,866
Other Segment [Member]	'	'
Total assets	$3,650,124	$1,087,727

Managements_Plans_for_Continui1

Management's Plans for Continuing Operations (Details Textuals) (USD $)	2 Months Ended	3 Months Ended				9 Months Ended
	Nov. 17, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Management's Plans for Continuing Operations	'	'	'	'	'	'	'
Net loss	'	($1,250,263)	($1,020,866)	($1,424,072)	($1,538,034)	($3,695,201)	($9,963,844)
Operating loss	'	-1,241,773	'	'	-1,531,638	-3,671,359	-9,943,877
Share based compensation expense	'	'	'	'	'	1,059,653	'
Patent expense	'	'	'	'	'	276,362	'
Operating loss from BluScience	'	'	'	'	'	192,399	'
Shares of stock sold	3,529,411	'	'	'	'	'	'
Shares of stock sold, selling price per share	$0.85	'	'	'	'	'	'
Gross proceeds from sale of stock	3,000,000	'	'	'	'	'	'
Net proceeds from sale of stock	$2,980,000	'	'	'	'	'	'

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	2 Months Ended
	Nov. 17, 2013
Shares of stock sold	3,529,411
Gross proceeds from sale of stock	$3,000,000
Shares of stock sold, selling price per share	$0.85
Net proceeds from sale of stock	2,980,000
Convertible promissory note per annum interest	6.00%
Sale of Stock 1 [Member]	'
Shares of stock sold	2,941,176
Gross proceeds from sale of stock	2,500,000
Shares of stock sold, selling price per share	$0.85
Sale of Stock 2 [Member]	'
Shares of stock sold	588,235
Gross proceeds from sale of stock	500,000
Shares of stock sold, selling price per share	$0.85
Cash fee	$20,000